pralsetinib sold brand name gavreto medication ret mutationpositive medullary thyroid cancer ret fusionpositive differentiated thyroid cancer dtc refractory radioactive iodine rai pralsetinib tyrosine kinase inhibitor taken common adverse reactions include increased aspartate aminotransferase ast decreased hemoglobin decreased lymphocytes decreased neutrophils increased alanine aminotransferase alt increased creatinine increased alkaline phosphatase fatigue constipation musculoskeletal pain decreased calcium hypertension decreased sodium decreased phosphate decreased pralsetinib approved medical use united states september european union november pralsetinib indicated treatment adults metastatic ret fusionpositive nonsmall cell lung cancer nsclc detected fda approved efficacy investigated multicenter openlabel multicohort clinical trial arrow participants aged whose tumors ret identification ret gene alterations prospectively determined local laboratories using either next generation sequencing fluorescence situ hybridization main efficacy outcome measures overall response rate orr response duration determined blinded independent review committee using recist trial conducted sites united states europe efficacy ret fusionpositive nsclc evaluated participants previously treated platinum orr ci responding participants responses lasting months efficacy also evaluated participants never received systemic orr participants ci responding participants responses lasting months us food drug administration fda granted application pralsetinib priority review orphan drug breakthrough therapy granted approval gavreto blueprint september committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product gavreto intended treatment people rearranged transfection retfusion positive nonsmall cell lung cancer applicant medicinal product roche registration pralsetinib approved medical use european union november httpsenwikipediaorgwikipralsetinib